Atherosclerosis core

动脉粥样硬化核心

• 批准号: 10628989
• 负责人: Edward A Fisher
• 金额: $ 21.49万
• 依托单位: NYU LONG ISLAND SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628989
• 关键词: Aorta; Arterial Fatty Streak; Arteries; Atherosclerosis; Biogenesis; Bioinformatics; Biology; Biometry; Catabolism; Cell Compartmentation; Cells; Characteristics; Confocal Microscopy; Data; Digestion; Endothelial Cells; Ensure; Family; Gene Expression; Gene Expression Profiling; Genomics; Histologic; Immunohistochemistry; Laboratories; Lesion; Lesion by Morphology; Lipids; Lipoproteins; Macrophage; Metabolic; Molecular; Myeloid Cells; Population; Procedures; Process; Program Research Project Grants; Reproducibility; Research Personnel; Sampling; Services; Stains; Standardization; Techniques; Technology; Tissues; Valsalva sinus; analytical tool; cell type; cost effectiveness; data management; experimental study; histological stains; instrumentation; laser capture microdissection; novel; single-cell RNA sequencing; tissue preparation; transcriptome sequencing

The Atherosclerosis Core (Core 3; C3) will be led by Dr. Edward Fisher and provide Program Project Grant (PPG) investigators with three complementary approaches for analyzing atherosclerotic lesions, lesion macrophages, and gene expression in myeloid cells and tissues investigated in the projects. First, C3 will provide histological staining, immunohistochemistry, and quantification of atherosclerotic lesions. Second, it will provide laser capture microdissection of macrophages and other types of cells in atherosclerotic lesions for analysis of gene expression changes. Third, C3 will provide expertise in aortic digestion to obtain specific cell compartments to provide samples to the NYU Genomic Technology Center (GTC) for RNA sequencing (RNA- seq) and single cell RNA-seq (scRNA-seq) analyses. These `omic' data will then undergo bioinformatic analyses under Core 1, which will oversee Administration, Data Management, Biostatistics, and Bioinformatics.By providing a central laboratory, C3 offers these services with optimal efficiency and cost- effectiveness, avoiding the need for PPG investigators to maintain the required instrumentation in their own laboratories or use expensive commercial services. By centralizing and standardizing procedures, C3 provides a common set of analytical tools to enable a unified understanding of molecular mechanisms involved in pathophysiologic processes of atherosclerosis and the biology of macrophages and endothelial cells. The Specific Aims of C3 are: 1. To provide comprehensive tissue analysis and quantification of atherosclerotic lesions; 2. To provide laser capture microdissection (LCM) of target cells, primarily macrophages, in atherosclerotic lesions for gene expression studies; 3. To prepare aortic tissue (by digestion and FACS) to provide samples to the GTC for RNA-seq and scRNA-seq (with the resulting data to be analyzed by Core 1).

动脉粥样硬化核心（核心3; C3）将由爱德华费舍尔博士领导，并提供计划项目补助金 (PPG)研究者用三种互补的方法分析动脉粥样硬化病变， 巨噬细胞，以及项目中研究的骨髓细胞和组织中的基因表达。首先，C3将 提供动脉粥样硬化病变的组织学染色、免疫组织化学和定量。二是会 提供动脉粥样硬化病变中巨噬细胞和其他类型细胞的激光捕获显微切割， 分析基因表达的变化。第三，C3将提供主动脉消化的专业知识，以获得特定的细胞， 隔室提供样本给纽约大学基因组技术中心（GTC）进行RNA测序（RNA- seq）和单细胞RNA-seq（scRNA-seq）分析。然后，这些“组学”数据将进行生物信息学处理， 核心1项下的分析，将监督行政、数据管理、生物统计和 生物信息学。通过提供中心实验室，C3以最佳的效率和成本提供这些服务- 有效性，避免了PPG研究人员自己维护所需仪器的需要 实验室或使用昂贵的商业服务。通过集中和标准化流程，C3提供了 一套通用的分析工具，使人们能够统一理解参与的分子机制， 动脉粥样硬化的病理生理过程以及巨噬细胞和内皮细胞的生物学。的 C3的具体目标是：1。为动脉粥样硬化提供全面的组织分析和量化 病变; 2.为了提供靶细胞（主要是巨噬细胞）的激光捕获显微切割（LCM）， 用于基因表达研究的动脉粥样硬化病变; 3.制备主动脉组织（通过消化和FACS）， 向GTC提供RNA-seq和scRNA-seq的样本（所得数据由核心1分析）。